Diagnostic and Prognostic Value of Salivary Biochemical Markers in Oral Squamous Cell Carcinoma

Lyudmila V. Bel’skaya 1,* , Elena A. Sarf 1, Denis V. Solomatin 2 and Victor K. Kosenok 3

1 Biochemistry Research Laboratory, Omsk State Pedagogical University, 14, Tukhachevsky str, 644043 Omsk, Russia; nemcha@mail.ru
2 Department of Mathematics and Mathematics Teaching Methods, Omsk State Pedagogical University, 14, Tukhachevsky str, 644043 Omsk, Russia; denis_2001j@bk.ru
3 Department of Oncology, Omsk State Medical University, 12, Lenina str, 644099 Omsk, Russia; victorkosenok@gmail.com
* Correspondence: belskaya@omgpu.ru

Received: 21 September 2020; Accepted: 13 October 2020; Published: 14 October 2020

Abstract: The purpose of the work is a comprehensive assessment of biochemical saliva markers for the diagnosis and prognosis of oral cancer. The group of patients included 68 patients with oral squamous cell carcinoma, 50 with non-cancerous diseases of the oral cavity, and 114 healthy volunteers. Before the start of treatment, 23 biochemical parameters of saliva were determined. Participants were monitored for six years to assess survival rates. The statistical analysis was performed by means of Statistica 10.0 and R package. A complex of metabolic changes occurring in saliva in oral cancer is described. It was shown that none of the studied parameters could be used to diagnose oral cancer in an independent variant; the use of combinations of parameters is more informative. The high prognostic value of the content of malondialdehyde (MDA) and the Na/K-ratio in saliva before treatment was established. Thus, the content of MDA < 7.34 nmol/mL and the Na/K-ratio > 1.09 c.u. is a prognostically unfavorable factor (HR = 7.88, 95% CI 1.10–54.62, p = 0.01876), which may be useful for optimizing the treatment of patients with oral cancer. It has been shown that saliva has great potential for the development of diagnostic and prognostic tests for oral cancer.

Keywords: saliva; oral squamous cell carcinoma; biochemical markers

1. Introduction

Cancer of the oral cavity and oropharynx takes the 8th place in the structure of the general incidence of malignant neoplasms and the 1st among the malignant tumors of the head and neck (excluding non-melanoma skin lesions). Oral squamous cell carcinoma (OSCC) is diagnosed in 90% of all cases of oral cancer [1]. Almost 300,000 new cases of the disease are observed every year in the world [2], of which 145,000 result in the death of the patient [3]. The overall five-year survival rate in such patients does not exceed 60%; the risk of relapse is 30% [4]. The peak incidence occurs at the age of about 60 years, but in the younger group in recent years, there has been an increase in the detection of oropharyngeal cancer associated with human papillomavirus (HPV) [5]. In Russia, the number of OSCC patients with stage III and IV is 61.7% and 81.1%, respectively, of the number of all tumors of this localization [6]. Therefore, the search for new methods for the early diagnosis of oral cancer remains an urgent task to date [7].

In connection with the visual localization of tumors of the oropharyngeal zone, the primary diagnosis is most often established based on examination and biopsy data [8]. In the current international practical recommendations, the standard diagnostic method is a computer tomography...
Various studies are devoted to the use of “omics” technologies, including genomic, transcriptomic, proteomic and metabolic profiling for the detection of biomarkers of oral cancer in tissues, blood, cell lines, urine, etc. [10–12]. However, the results obtained are currently not included in clinical recommendations and are not used in clinical practice.

It is logical to assume that the use of saliva is most promising for the detection of oral cancer. Obtaining saliva samples is non-invasive; there is a lower risk of infection, while direct contact of saliva with oral pathologies can contribute to the earlier detection of relevant diseases [13,14]. More than 100 biomarkers have shown differential levels in saliva of OSCC patients [1,15,16]. They include a large number of proteins that encompass cell surface molecules (CD44sol, CA-125) [17,18]; cytoskeletal fragments (CYFRA 21-1) [19]; intracellular proteins (ZNF-510, Mac-2 binding protein) [20,21]; proteases (MMP, cathepsin V, kallikrein 5 and ADAM9) [22,23]; inflammation-related proteins (CRP, defensin-1) [24,25]; mRNA signatures (DUSP1, OAZ1, SAT and H3F3A) [26], and some non-coding RNAs (miRNA, in particular miR-9, miR-134 and miR-191, and circular RNA) [27–29]. IL-1b, IL-6, IL-8, MIP-1b, eotaxin and IFN-g and TNF-a showed significant differences between OSCC patients and controls [30]. Salivary-mutated and salivary-methylated DNA, HPV DNA, telomerase levels, specific microbiota of the oral cavity [31], biomarkers of metabolic and oxidative stress [32] and inorganic ion concentration [33] demonstrated the potential of biomarkers. In a number of studies, the content of volatile organic compounds was also determined [34].

The prognostic significance of various factors has been studied in a sufficient number of studies, but at the moment, unfortunately, no single indicator or combination thereof has been found that unequivocally allows us to assess the prognosis of the course of the disease and the risk of its relapse [24,35,36].

The aim of the study was a comprehensive assessment of the biochemical markers of saliva in order to diagnose and predict the course of oral cancer.

2. Materials and Methods

2.1. Study Design

The study involved volunteers who were divided into three groups: the main, the comparison and the control groups. The main group included patients with a histologically confirmed diagnosis of oral cancer (n = 68, including larynx and nasopharynx—32, oral mucosa—21, tongue—15; in all cases, the histological type of tumor is squamous cell carcinoma, stages I–IV according to UICC TNM staging system, 7th edition). The comparison group included patients with benign tumors of the oral cavity (n = 50, including polyps—6, papillomas—8, cysts—6, adenomas—30). The control group included patients without pathologies of the oral cavity and significant systemic pathologies, including diabetes mellitus, oncological diseases, etc. (n = 114). The inclusion criteria were considered: the age of patients 30–75 years, the absence of any treatment at the time of the study, including surgery, chemotherapy or radiation, the absence of signs of active infection (including purulent processes), the absence of inflammatory diseases of the oral cavity and periodontium. Exclusion criteria: lack of histological verification of the diagnosis. The patients of the main group and the comparison group did not have concomitant diseases that could affect the biochemical composition of saliva, including diabetes mellitus, inflammatory diseases, autoimmune diseases, etc.

The study was approved at a meeting of the ethics committee of the Clinical Oncology Center in Omsk dated 21 July 2016, protocol No. 15.

2.2. Collection and Preparation of Saliva Samples

All participants had saliva sampling before starting treatment. Saliva samples (5 mL) were collected on an empty stomach after rinsing the oral cavity with water in the range of 8–10 h in the morning by spitting in sterile polypropylene tubes, the salivation rate (mL/min) was calculated.
Saliva samples were centrifuged (10,000× g for 10 min) (CLb-16, Moscow, Russia). Biochemical analysis of saliva was performed immediately without storage and freezing [37].

2.3. Biochemical Analysis of Saliva Samples

In all saliva samples, 23 biochemical parameters were determined [38]. The concentration of potassium and sodium ions (mmol/L) was determined using the KAPEL-105M capillary electrophoresis system (Lumex, St. Petersburg, Russia); Ca/P and Na/K-ratio were calculated [39]. The total calcium content (mmol/L) was determined photometrically on a StatFax 3300 semi-automatic biochemical analyzer (Awareness Technology, Palm City, FL, USA) by reaction with Arsenazo III, phosphorus (mmol/L) by the reaction of molybdenum acid ammonium, chlorides (mmol/L) by reaction with mercury thiocyanate. Urea concentration (mmol/L) was determined photometrically by the Bertlott urease-salicylate method, total protein (g/L) by reaction with pyrogallol red, albumin (g/L) by reaction with green bromocresol, uric acid (UA, mmol/mL) by uricase method, sialic acids (SA, mmol/L) according to the Hess method. Alkaline phosphatase activity (ALP, U/L) was determined by the Bessey–Lowry–Brock endpoint method, lactate dehydrogenase (LDH, U/L) by the kinetic ultraviolet method according to the NADH (Nicotinamide Adenine Dinucleotide) oxidation rate, gamma glutamyl transferase (GGT, U/L) kinetic method using L-gamma-glutamyl-3-carboxy-4-nitroanilide as a Zeitz–Persin substrate, α-amylase (U/L) by kinetic method for the hydrolysis of CNP-oligosaccharide with the formation of 2-chloro-4-nitrophenol. The activity of superoxide dismutase (SOD, c.u.) was determined by the accumulation of the product of auto-oxidation of adrenaline by the superoxide anion radical in an alkaline medium, catalase (CAT, mcat/L) by the rate of decrease of hydrogen peroxide in the incubation medium. The content of substrates for lipid peroxidation processes (diene conjugates—DC, triene conjugates—TC, Schiff bases—SB, c.u.) was determined spectrophotometrically by the Volchegorsky method. The content of malondialdehyde (MDA, nmol/mL) was determined by reaction with thiobarbituric acid. The level of middle molecular toxins was determined by ultraviolet spectrophotometry at wavelengths of 254 and 280 nm, the ratio MM 280/254 nm was calculated (MM, c.u.).

2.4. Statistical Data Processing

Statistical analysis was performed using the programs Statistica 13.3 EN (StatSoft, Tulsa, OK, USA); R version 3.6.3; RStudio Version 1.2.5033; FactoMineR version 2.3. (RStudio, version 3.2.3, Boston, MA, USA). The sample was described nonparametrically using the Mann–Whitney U-test and the Kruskal–Wallis H-test by calculating the median (Me) and interquartile range in the form of the 25th and 75th percentiles (LQ; UQ). Differences were considered statistically significant at \( p < 0.05 \).

Checking whether a pair of sets of values of the observed indicator belongs to one class was performed using the Wilcoxon pair test at a significance level of 0.05. To search for blocks of pairwise equivalent data, denoted by the same letters on the graphs, the Bron–Kerbosch algorithm was used. A principal component analysis (PCA) was performed using the PCA program in R [40]. The significance of the correlation is determined by the correlation coefficient (r): strong—\( r = \pm 0.700 \) to \( \pm 1.00 \), medium—\( r = \pm 0.300 \) to \( \pm 0.699 \), weak—\( r = 0.00 \) to \( \pm 0.299 \). The rate of change of individual biochemical parameters was quantified using the ratio of natural logarithms (LnRR), with LnRR (indicator) = \( \ln \) (OSCC or Comparison/Control value). Medians and interquartile range presented in figures were calculated using non-transformed data.

Kaplan-Meier method was applied to calculate survival curves and comparison was made using the Log-rank test for univariate analysis (Statistica 10.0, StatSoft). Prognostic factors were analyzed by multivariate analysis using Cox’s proportional hazard model. Overall survival (OS) was computed from the date of diagnosis to the date of death (Complete) or the date of last follow-up (Censored). Survival data were obtained until December 2019.
3. Results

3.1. Biochemical Saliva Markers in the Diagnosis of OSCC

At the first stage, the biochemical composition of the saliva of healthy volunteers and patients with malignant and non-malignant neoplasms in the oral cavity was compared (Table 1). It was shown that against the background of pathological processes in the oral cavity, an increase in the concentration of electrolyte components of saliva is observed, while the protein content decreases. A statistically significant increase in the activity of metabolic enzymes was established for both the main group and the comparison group, however, the activity of catalase in both cases decreases compared to the control group. An increase in the content of lipid peroxidation products (diene, triene conjugates and Schiff bases) was also noted, while the concentration of MDA remained practically unchanged. The ratio MM is also growing, which indicates an increase in the level of endogenous toxins.
Table 1. The results of biochemical analysis of the studied groups.

| Indicators                  | Control Group, n = 114 (1) | Comparison Group, n = 50 (2) | Oral Cancer, n = 68 (3) | Kruskal–Wallis Test (H, p) |
|-----------------------------|-----------------------------|-------------------------------|-------------------------|---------------------------|
| Flow rate, mL/min           | 0.87 (0.72; 0.99)           | 0.81 (0.74; 0.94)             | 0.78 (0.64; 0.97)       | 1.079, 0.5836            |
| Electrolytes                |                             |                               |                         |                           |
| Calcium, mmol/L             | 1.26 (1.03; 1.61)           | 1.38 (1.10; 1.69)             | 1.39 (1.14; 1.85)       | 4.999, 0.1003            |
| Phosphorus, mmol/L          | 4.36 (3.39; 5.58)           | 4.70 (3.62; 6.38)             | 4.29 (3.03; 6.19)       | 1.350, 0.5091            |
| Sodium, mmol/L              |                             |                               |                         |                           |
| Potassium, mmol/L           | 10.5 (8.6; 13.3)            | 12.0 (8.9; 15.6)              | 11.0 (8.3; 16.1)        | 2.291, 0.3181            |
| Na/K                        |                             |                               |                         |                           |
| Chlorides, mmol/L           | 23.7 (19.4; 29.6)           | 26.1 (21.7; 33.9)             | 30.1 (21.9; 39.5)       | 12.38, 0.0020 *          |
| Protein Metabolism          |                             |                               |                         |                           |
| Protein, g/L                | 1.11 (0.78; 1.53)           | 0.75 (0.49; 1.23)             | 0.84 (0.47; 1.59)       | 8.581, 0.0137 *          |
| Albumin, g/L                | 0.24 (0.17; 0.36)           | 0.34 (0.19; 0.48)             | 0.36 (0.19; 0.67)       | 11.53, 0.0031 *          |
| Urea, mmol/L                | 6.76 (4.35; 8.78)           | 8.67 (5.73; 13.48)            | 8.66 (4.62; 11.29)      | 7.823, 0.0200 *          |
| Uric acid, mmol/mL          | 76.8 (25.2; 161.2)          | 124.5 (67.3; 193.6)           | 93.0 (43.2; 182.9)      | 9.346, 0.0093 *          |
| Sialic acids, mmol/L        | 0.189 (0.134; 0.311)        | 0.186 (0.131; 0.250)          | 0.220 (0.140; 0.336)    | 1.147, 0.5634            |
| Enzymes                     |                             |                               |                         |                           |
| ALP, U/L                    | 60.84 (39.11; 84.75)        | 70.62 (47.81; 99.96)          | 73.88 (49.98; 109.74)   | 5.128, 0.0770            |
| LDH, U/L                    | 1008.0 (607.9; 1702.0)      | 1471.0 (1121.0; 2098.0)       | 1441.0 (864.8; 2028.0)  | 11.30, 0.0035 *          |
| GGT, U/L                    | 18.6 (15.4; 23.0)           | 22.4 (19.7; 24.7)             | 23.2 (17.9; 27.0)       | 21.45, 0.0000 *          |
| α-amylase, U/L              | 178.8 (74.3; 382.9)         | 316.1 (127.2; 503.7)          | 315.1 (196.3; 519.5)    | 8.345, 0.0154 *          |
| Catalase, mcat/L            | 4.52 (3.60; 5.90)           | 3.48 (2.34; 5.13)             | 3.00 (2.18; 4.56)       | 27.79, 0.0000 *          |
| SOD, c.u.                   | 61.8 (36.8; 115.8)          | 63.2 (28.9; 131.6)            | 68.4 (26.3; 123.7)      | 0.0521, 0.9743            |
For indicators that demonstrate differences between the studied groups (Kruskal–Wallis criterion, Table 1), diagrams are additionally constructed (Figure 1). It was shown that the maximum differences are observed between the control group and patients with pathologies of the oral cavity (both benign and malignant). Differences between the three groups are confirmed for chlorides and Schiff bases (Groups A, AB and B, Figure 1).

The data analyzed by the PCA method contained 232 records with 11 quantitative and 1 qualitative variables in each, which is quite representative. The inertia of the first measurements shows whether there are strong relationships between the variables and indicates the number of measurements that need to be studied. The first two measurements cover 40.62% of the total inertia of the data set (28.78% of the first axis and 11.84% of the second axis); this means that 40.62% of the total variability is explained by two PCs. This percentage is relatively high and, therefore, the two-dimensional plane well represents the variability of the data (Figure 2a). As a result of PCA, we obtained the distribution of parameters along the axes of the factor plane (Figure 2b, \(p < 0.05\)). For PC1 (horizontal axis), high correlation coefficients were obtained for albumin \(r = 0.80\) and protein \(r = 0.72\), medium strength correlations for chlorides \(r = 0.65\), LDH \(r = 0.62\), catalase \(r = 0.61\), GGT \(r = 0.58\), uric acid \(r = 0.44\) and urea \(r = 0.42\). For PC2 (vertical axis), a high correlation coefficient was noted only for the ratio MM \(r = 0.77\), while the average strength for uric acid \(r = 0.52\) and catalase \(r = -0.44\). As can be seen on the given factor plane (Figure 2a), this set of indicators makes it possible to distinguish between a control group and a group of patients with diseases of the oral cavity, however, in this way it is not possible to differentiate between benign and malignant pathologies.

### Table 1. Cont.

| Indicators                     | Control Group, \(n = 114\) | Comparison Group, \(n = 50\) | Oral Cancer, \(n = 68\) | Kruskal–Wallis Test \((H, p)\) |
|-------------------------------|-----------------------------|-------------------------------|--------------------------|-----------------------------|

| Lipoperoxidation Products and Endogenous Intoxication Rates |
|------------------------------------------------------------|
| Diene Conjugates, c.u.                                     |
| 3.90 (3.74; 4.02)                                          |
| 3.94 (3.78; 4.11)                                          |
| 3.93 (3.76; 4.16)                                          |
| 3.259, 0.1960                                              |
| Triene Conjugates, c.u.                                    |
| 0.885                                                      |
| (0.816; 1.042)                                             |
| 0.911                                                      |
| (0.810; 1.080)                                             |
| 0.923                                                      |
| (0.837; 1.047)                                             |
| 0.5642, 0.7542                                             |
| Schiff Bases, c.u.                                         |
| 0.534                                                      |
| (0.494; 0.570)                                             |
| 0.545                                                      |
| (0.497; 0.653)                                             |
| 0.558                                                      |
| (0.513; 0.715)                                             |
| 12.95, 0.0015 *                                           |
| MDA, nmol/ml.                                               |
| 6.92 (6.15; 9.06)                                          |
| 6.84 (5.73; 8.72)                                          |
| 6.58 (5.56; 7.78)                                          |
| 2.716, 0.2572                                              |
| MM 280/254 nm                                              |
| 0.778                                                      |
| (0.694; 0.878)                                             |
| 0.918                                                      |
| (0.818; 1.036)                                             |
| 0.895                                                      |
| (0.795; 0.990)                                             |
| 30.09, 0.0000 *                                           |

Note. \(p_{1-2}\), \(p_{1-3}\)—statistically significant differences compared with control group (Mann–Whitney U-criterion); \(H\)—Kruskal–Wallis criterion; \(p\)—significance level; *—differences are statistically significant, \(p < 0.05\).
For indicators that demonstrate differences between the studied groups (Kruskal–Wallis criterion, Table 1), diagrams are additionally constructed (Figure 1). It was shown that the maximum differences are observed between the control group and patients with pathologies of the oral cavity (both benign and malignant). Differences between the three groups are confirmed for chlorides and Schiff bases (Groups A, AB and B, Figure 1).

Figure 1. Comparison of statistical characteristics in the studied groups. The cross is mean; the rectangle corresponds to the first and third quartiles. The letters indicate the differences between the groups. Means without a common letter statistically differ ($p < 0.05$).
shows whether there are strong relationships between the variables and indicates the number of measurements that need to be studied. The first two measurements cover 40.62% of the total inertia of the data set (28.78% of the first axis and 11.84% of the second axis); this means that 40.62% of the total variability is explained by two PCs. This percentage is relatively high and, therefore, the two-dimensional plane well represents the variability of the data (Figure 2a). As a result of PCA, we obtained the distribution of parameters along the axes of the factor plane (Figure 2b, p < 0.05). For PC1 (horizontal axis), high correlation coefficients were obtained for albumin ($r = 0.80$) and protein ($r = 0.72$), medium strength correlations for chlorides ($r = 0.65$), LDH ($r = 0.62$), catalase ($r = 0.61$), GGT ($r = 0.58$), uric acid ($r = 0.44$) and urea ($r = 0.42$). For PC2 (vertical axis), a high correlation coefficient was noted only for the ratio MM ($r = 0.77$), while the average strength for uric acid ($r = 0.52$) and catalase ($r = -0.44$). As can be seen on the given factor plane (Figure 2a), this set of indicators makes it possible to distinguish between a control group and a group of patients with diseases of the oral cavity, however, in this way it is not possible to differentiate between benign and malignant pathologies.

![Figure 2.](image)

If we consider the change in the parameters relative to the control group, then we can note a unidirectional character both for the comparison group and for the oral cancer group (Figure 3).
If we consider the change in the parameters relative to the control group, then we can note a unidirectional character both for the comparison group and for the oral cancer group (Figure 3).

**Figure 3.** The intensity of the difference \((\ln RR = \ln (\text{OSCC}/\text{Control}) \text{ and } \ln RR = \ln (\text{Comparison}/\text{Control}))\) by 11 biochemical parameters from the control group. Similar letters do not differ much \((\alpha = 0.05)\). The dashed line represents the zero level \((\ln RR = 0)\). Significance of differences from 0 was checked using the t-test of one sample and indicated by numbers (“0” is not significant; “1” is \(p < 0.05\); “2” is \(p < 0.01\); “3” is \(p < 0.001\)).

The presence of outliers is illustrated by the heterogeneity of the observed values, for example, for the \(\ln RR\) (GGT) in the comparison group, the average value increased statistically significantly, but there are many outliers with decreased values, that is, one cannot speak of a guaranteed increase in the values of this indicator, even having confirmation in the control group. One of the probable reasons may be the combination of all stages of oral cancer in one group; therefore, at the next stage of the study, the main group was further divided into stages (Table 2).
Table 2. Biochemical indicators of saliva in OSCC, depending on the stage I–IV.

| Indicator          | St I, n = 10 | St II, n = 16 | St III, n = 20 | St IV, n = 22 |
|--------------------|--------------|---------------|----------------|--------------|
| **Flow rate, mL/min** | 0.80 (0.67; 0.95) | 0.78 (0.62; 0.98) | 0.81 (0.70; 1.01) | 0.76 (0.62; 0.93) |
| **Electrolytes**   |              |               |                |              |
| **Calcium, mmol/L** | 1.23 (1.00; 1.45) | 1.52 (1.31; 2.24) | 1.55 (1.20; 1.86) | 1.27 (0.79; 1.94) |
| Ca/P               | 0.238 (0.203; 0.276) | 0.375 (0.215; 0.550) | 0.275 (0.185; 0.568) | 0.441 (0.254; 0.861) |
| Sodium, mmol/L     | 14.9 (4.5; 16.1) | 8.6 (6.5; 11.9) | 7.1 (5.4; 10.9) | 10.0 (6.0; 14.0) |
| Potassium, mmol/L  | 14.4 (10.5; 18.6) | 14.1 (8.5; 17.7) | 13.3 (9.0; 16.5) | 9.2 (4.0; 15.6) |
| **Enzymes**        |              |               |                |              |
| ALP, U/L           | 94.53 (33.68; 123.86) | 78.23 (64.10; 139.07) | 59.76 (47.81; 98.87) | 72.80 (54.33; 110.82) |
| LDH, U/L           | 1094.8 (586.5; 1546.0) | 1903.5 (1226.5; 2316.5) | 1756.0 (938.7; 2179.0) | 1295.5 (702.9; 1928.0) |
| GGT, U/L           | 23.7 (22.9; 28.8) | 24.9 (17.3; 27.4) | 24.6 (17.1; 28.9) | 19.8 (17.9; 23.9) |
| **Uric acid, nmol/mL** | 106.85 (41.83; 187.51) | 102.16 (56.23; 188.14) | 117.31 (35.31; 192.48) | 71.96 (40.00; 136.11) |
| **Protein Metabolism** |              |               |                |              |
| **Protein, g/L**   | 0.68 (0.55; 1.32) | 0.87 (0.53; 1.63) | 0.94 (0.44; 1.71) | 0.84 (0.45; 1.31) |
| **Albumin, g/L**   | 0.39 (0.10; 0.57) | 0.39 (0.22; 0.53) | 0.48 (0.25; 0.91) | 0.35 (0.15; 0.57) |
| **Urea, mmol/L**   | 8.71 (5.09; 13.39) | 9.21 (4.98; 13.94) | 7.90 (5.08; 10.30) | 8.02 (3.02; 10.22) |
| **ALP, U/L**       |              |               |                |              |
| **LDH, U/L**       |              |               |                |              |
| **GGT, U/L**       |              |               |                |              |
| **α-amylase, U/L** |              |               |                |              |
| **Catalase, mcat/L** |              |               |                |              |
| **SOD, c.u.**      | 55.3 (23.7; 182.9) | 71.1 (28.9; 150.0) | 65.8 (25.0; 128.9) | 67.1 (30.3; 88.2) |
In an attempt to separate the oral cancer group by stages, the PCA-analyzed data contained 66 records, 24 variables each, of which 19 quantitative variables are illustrative and 1 qualitative variable is illustrative, which is quite representative. The first two measurements cover 81.98% of the total inertia of the data set (46.10% of the first axis and 35.88% of the second axis); this means that 81.98% of the total variability is explained by two PCs. This percentage is relatively high and, therefore, the two-dimensional plane well represents the variability of the data. It follows that more than 1/3 of all observations will be well interpreted. As a result of PCA, we obtained the distribution of parameters along the axes of the factor plane (Figure 2c,d; \( p < 0.001 \)). For PC1 (horizontal axis), high correlation coefficients were obtained for Schiff bases (\( r = 0.83 \)) and triene conjugates (\( r = 0.79 \)), average strength correlation coefficients for albumin (\( r = 0.51 \)), urea (\( r = 0.51 \)), potassium (\( r = 0.51 \)), catalase (\( r = 0.47 \)), protein (\( r = 0.47 \)) and LDH (\( r = 0.40 \)). For PC2 (vertical axis), high correlation coefficients correspond to potassium (\( r = 0.72 \)) and albumin (\( r = 0.72 \)); average correlation strengths were obtained for chlorides (\( r = 0.63 \)), protein (\( r = 0.57 \)), uric acid (\( r = 0.53 \)), GGT (\( r = 0.45 \)), sodium (\( r = 0.42 \)), Schiff bases (\( r = -0.41 \)) and triene conjugates (\( r = -0.49 \)). Nevertheless, as can be seen in the above figures, only stages I–III and stage IV can be separated between each other (Figure 2c,d).

The calculation of the Kruskal–Wallis N-test values showed that the separately taken stages of oral cancer and the control group reliably differ in a fairly large number of indicators (Table 3), while comparing the same stages with the comparison group shows differences in only two indicators (phosphorus and Na/K-ratio, Table 3). Charts were constructed based on significantly different indicators (Figure 4a,b), which show the change in the considered indicators depending on the stage of the disease.

The calculations showed that none of the considered indicators in their own version could be used to diagnose oral cancer; however, a combination of a number of indicators allows us to differentiate the groups among themselves. So, according to the parameters “albumin + protein + MM + uric acid” (Figure 2), it is possible to distinguish the combined group (OSCC + Comparison Group) from the control group, and to separate the stages among themselves inside the OSCC group, you need to use other parameters of the “Schiff base + triene conjugates + potassium + albumin” (Figure 4). However, it is not possible to distinguish between stages of oral cancer I–III and non-malignant diseases of the oral cavity using only the parameters considered.
Table 3. The values of the Kruskal–Wallis criterion when comparing patients with OSCC by stages with a control group and a comparison group.

| Indicators                        | Kruskal–Wallis Test ($H, p$) | Control Group, $n = 114$ | Comparison Group, $n = 50$ |
|-----------------------------------|-------------------------------|--------------------------|-----------------------------|
| **Electrolytes**                  |                               |                          |                             |
| Calcium, mmol/L                   | 8.728, 0.0683                 | 4.776, 0.3111            |
| Phosphorus, mmol/L                | 10.72, 0.0299 *               | 10.41, 0.0341 *          |
| Ca/P                              | 7.739, 0.1016                 | 6.252, 0.1811            |
| Sodium, mmol/L                    | 5.818, 0.2140                 | 2.588, 0.6289            |
| Potassium, mmol/L                 | 8.750, 0.0677                 | 4.840, 0.3041            |
| Na/K                              | 13.19, 0.0104 *               | 12.58, 0.0135 *          |
| Chlorides, mmol/L                 | 20.41, 0.0004 *               | 8.900, 0.0637            |
| **Protein Metabolism**            |                               |                          |                             |
| Protein, g/L                      | 3.459, 0.4842                 | 1.726, 0.7859            |
| Albumin, g/L                      | 12.01, 0.0173 *               | 3.487, 0.4799            |
| Urea, mmol/L                      | 4.783, 0.3016                 | 1.164, 0.8063            |
| Uric acid, mmol/mL                | 2.906, 0.5738                 | 1.972, 0.7410            |
| Sialic acids, mmol/L              | 6.715, 0.1518                 | 7.317, 0.1201            |
| **Enzymes**                       |                               |                          |                             |
| ALP, U/L                          | 5.660, 0.2260                 | 1.582, 0.8121            |
| LDH, U/L                          | 10.19, 0.0374 *               | 4.283, 0.3690            |
| GGT, U/L                          | 16.42, 0.0025 *               | 6.669, 0.1545            |
| α-amylase, U/L                    | 12.41, 0.0145 *               | 6.313, 0.1770            |
| Catalase, mcat/L                  | 28.05, 0.0000 *               | 4.612, 0.3294            |
| SOD, c.u.                         | 0.2268, 0.9940                | 0.2448, 0.9931           |
| **Lipperoxidation Products and Endogenous Intoxication Rates** | | | |
| Diene Conjugates, c.u.            | 7.406, 0.1159                 | 6.668, 0.1545            |
| Triene Conjugates, c.u.           | 8.209, 0.0842                 | 7.210, 0.1252            |
| Schiff Bases, c.u.                | 20.59, 0.0004 *               | 6.190, 0.1854            |
| MDA, nmol/mL                      | 9.623, 0.0473 *               | 7.446, 0.1141            |
| MM 280/254 nm                     | 17.65, 0.0014 *               | 3.365, 0.4987            |

Note. $H$—Kruskal–Wallis criterion; $p$—significance level; *—differences are statistically significant, $p<0.05$. 
Figure 4. The intensity of the difference LnRR = Ln(OSCC/Control) for 11 parameters relative to the control group according to stages (a) and LnRR = Ln(OSCC/Comparison) for 2 parameters relative to the comparison group (b). Similar letters do not differ much (α = 0.05). The dashed line represents the zero level (LnRR = 0). Significance of differences from 0 was checked using the t-test of one sample and indicated by numbers (“0” is not significant; “1” is \( p < 0.05 \); “2” is \( p < 0.01 \); “3” is \( p < 0.001 \)).
3.2. Prognostic Value of Biochemical Saliva Markers in OSCC

For the study group, the median of overall survival (OS) was 30.4 months, and disease-free survival (DFS) was 16.0 months. According to the results of multivariate regression analysis, it was found that the concentration of malondialdehyde (MDA) and the Na/K-ratio in saliva are associated with survival rates for OSCC patients (Figure 5a,b).

The overall survival of OSCC patients depending on the concentration of MDA and Na/K ratio in saliva: (a) MDA > 7.34 nmol/mL (curve 1) and MDA < 7.34 nmol/mL (curve 2); (b) Na/K < 1.09 c.u. (curve 1) and Na/K > 1.09 c.u. (curve 2); (c) multivariate regression analysis of overall survival: MDA > 7.34 nmol/mL and Na/K < 1.09 c.u. (curve 1); MDA < 7.34 nmol/mL and Na/K > 1.09 c.u. (curve 2); other combinations (curve 3); (d) multivariate regression analysis of the disease-free survival: MDA > 7.34 nmol/mL and Na/K < 1.09 c.u. (curve 1); MDA < 7.34 nmol/mL and Na/K > 1.09 c.u. (curve 2); other combinations (curve 3).

The average values for the OSCC group (for MDA—7.34 nmol/mL, for Na/K—1.09 c.u.) were used as threshold values for indicators of OS. The MDA concentration of more than 7.34 nmol/mL ($p = 0.17155$) and the Na/K-ratio of less than 1.09 c.u. are predictively favorable ($p = 0.06187$, Table 4).
The combination of both parameters is a more effective prognostic sign \( (p = 0.01876, \text{Table } 4) \). For patients with a favorable prognosis \((\text{MDA} > 7.34 \text{ and } \text{Na/K} < 1.09)\), the 1-year overall survival rate decreases sharply when switching from a favorable to an unfavorable prognosis from 81.8 to 50.1%, 3-year from 81.8 to 20.1%, 5-year-old from 53.7 to 0% (Figure 5c). The combination of intermediate values in terms of survival is closer to the group with a favorable prognosis; the differences between the groups are statistically unreliable. For a combination of parameters, indicators of DFS were additionally calculated (Figure 5D). In this case, median of DFS with a favorable prognosis was 40.7 months, with an unfavorable prognosis—6.7 months, in all other cases—21.4 months \((HR = 4.20, 95\% \text{ CI } 0.74–23.24, p = 0.05775)\).

### Table 4. Analysis of biochemical saliva parameters affecting overall survival of OSCC patients.

| Indicators | Category | HR (95% CI) | \(p\)-Value | OS, Months |
|------------|----------|-------------|-------------|------------|
| MDA, nmol/mL | \(<7.34, n = 42\) | 1 | 0.17155 | 25.4 |
| | \(>7.34, n = 26\) | 0.45 (0.15–1.37) | 0.06187 | 36.8 |
| Na/K, c.u. | \(<1.09, n = 39\) | 0.45 (0.15–1.37) | 0.06187 | 44.0 |
| | \(>1.09, n = 29\) | 1.49 (0.51–4.36) | 0.01876 | 15.5 |
| MDA + Na/K | Favorable prognosis, \(n = 16\) | 1 | 0.01876 | 49.3 |
| | Other combinations, \(n = 35\) | 1.40 (0.33–5.86) | \* | 38.1 |
| | Unfavorable prognosis, \(n = 17\) | 7.88 (1.10–54.62) | \* | 9.0 |

Note. OS—overall survival; \*—differences are statistically significant, \(p < 0.05\).

### 4. Discussion

It was established that against the background of cancer and benign pathologies of the oral cavity, a change in the metabolic profile of saliva occurs. Largely, the changes relate to protein metabolism: the total protein content decreases, but the content of albumin, urea and uric acid increases (Table 1). The activity of metabolic enzymes (LDH, GGT and \(\alpha\)-amylase) increases, while the activity of antioxidant enzymes, in particular catalase, decreases, and the content of toxic metabolites: Schiff bases and MM increases. Among electrolyte components, only an increase in chloride concentration is statistically significant. The observed changes as a whole fit into the picture of metabolic changes taking place against the background of oncological processes in the human body. In oral cancer, because of genetic changes, significant changes occur in critical metabolic pathways, such as glycolysis, tricarboxylic acid cycle, pentose phosphate cycle, polyamine synthesis, urea metabolism, etc. \([41,42]\). The imbalance of the lipid peroxidation system and antioxidant protection of saliva occurs, the activity of the enzymatic link decreases (catalase), and the role of the non-enzymatic link (albumin, uric acid) increases. Antioxidant saliva compounds are closely associated with oral cancer, and the oxidative radicals of saliva definitely reflect the stage of oral cancer and can be used to detect it in the early stages \([43]\). It was previously found that the content of carbonyl derivatives significantly increases in the saliva of OSCC patients, due to the direct effect of free radicals on saliva proteins, which is an indicator of oxidative damage to proteins \([44]\). Because of oxidative damage, protein toxins accumulate in saliva, which is expressed in a significant increase in the MM content against the background of a decrease in the total protein content (Tables 1 and 2). MDA is the final product of lipid peroxidation; its content is also used to characterize the degree of oxidation and antioxidant imbalance \([45]\). The level of MDA in saliva showed a statistically significant increase in the groups of precancerous diseases and cancer. MDA itself is also highly toxic and can cause carcinogenesis in the oral cavity \([46]\). As a convenient oxidation marker for studying the antioxidant potential of saliva, a general antioxidant capacity (AOC) is proposed \([47]\). The AOC of saliva decreases with precancerous diseases of the oral cavity, such as leukoplakia, lichen planus, erythroplakia, and oral cancer \([32]\). In our case, it was shown that the content of the main enzyme of the antioxidant protection of saliva, catalase, decreases, but the activity...
of superoxide dismutase does not significantly change, while for the non-enzymatic link of antioxidant protection, even an increase in concentrations is observed. Apparently, in this case, compensatory mechanisms are included in the work, and therefore, to understand the processes that occur against the background of oral cancer, it is necessary to consider not generalized indicators, but individual links of the saliva antioxidant defense system, in particular, catalase [48].

It is noted that with oral cancer, the activity of metabolic enzymes of saliva significantly increases. Earlier in the literature, this was noted only for LDH, whose activity is increased in the saliva of patients with leukoplakia and OSCC [49,50]. An increase in LDH activity may be due to the intensification of the production of lactate from pyruvate under anaerobic conditions, which is a key feature of cancer cells [51]. The important role of the glutathione system in antioxidant defense is known; GGT-dependent prooxidant reactions are involved in the inhibition of cancer cell proliferation [52,53]. The revealed increase in the activity of α-amylase according to published data can also be a diagnostically important sign; however, the presence of a large number of outliers (Figure 3) indicates the heterogeneity of the distribution of this parameter within the studied groups and its low reliability [54].

Against the background of OSCC, according to some data, the author noted an increase in the level of calcium, inorganic phosphate, magnesium, and sodium and a decrease in the level of potassium [55]. A change in the ionic composition may be associated with oral dehydration of OSCC [33,56]; however, in this case, a change in the salivation rate of saliva and an increase in the concentration of other components, for example, protein, would also be noted. The increase in the content of electrolyte components may be associated with a violation of the structural properties of saliva and changes in protein metabolism against pathological processes in the oral cavity. Based on the theory of the micellar structure of saliva, electrolyte components are part of the diffuse layer and stabilize calcium phosphate micelles, but they can be released when the balance is unbalanced [39]. This process should be considered as secondary, since statistically significant differences between the groups were revealed only for chlorides. Nevertheless, in recent decades, more and more scientific data confirm the role of ion channels in the development of various forms of cancer [57]. Both potassium-selective pores and chloride permeability are considered the most active channels in oncogenesis. High levels of proliferation, active migration, and invasion into non-tumor tissues are specific properties of neoplastic transformation. All these actions require a partial or full participation of the activity of the chloride channel. Another study showed that chloride ions play an important role in the progression of the cell cycle by regulating the expression of p21 via the p53-independent pathway in human gastric cancer cells [58]. So, in the Cl-substituted medium (replacement of chloride ions by nitrate ions), a decrease in the intracellular concentration of chlorides occurred and inhibition of cell growth was observed due to the stop of the cell cycle in the G0/G1 phase. Thus, the likely role of chlorides in the development of oral cancer may be wider, which requires further research in this direction.

When taking into account the stage of the disease, lipid peroxidation products come to the fore, the level of which increases significantly in the advanced stages of the disease (Table 2). It was shown by PCA that only stage IV disease can be isolated using the described parameters. Thus, it was found that the saliva of patients in the control group was significantly different from the saliva of patients with oral pathologies, while patients with non-cancerous pathologies and patients with stages I–III of OSCC can be differentiated only from advanced stages of the disease.

It is interesting to note that the metabolic changes occurring in saliva against the background of oral cancer can be used to predict the outcome of the disease (Table 4). Perhaps the use of MDA for these purposes and the Na/K-ratio of saliva are not described in the literature. The poor prognosis and early recurrence of OSCC is known to correlate with the simultaneous high levels of C-reactive protein (CRP), cancer-embryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA), elevated white blood cell count, absolute neutrophil and platelet count, low expression of Caspase-3, high expression of p53 and bcl-2, and no reduction in Ki-67 expression in tumor tissue. A decrease in the Ki-67 index at the treatment stages, high expression of Caspase-3, low expression of bcl-2 and p53, low levels of CRP, CEA and SCCA, and HPV-positive tumor status are associated with a favorable prognosis of
the course of the tumor process [35]. The use of miRNAs as prognostic biomarkers in OSCC has been described [59]. The possibility of using the CRP/albumin ratio to determine the prognosis of OSCC has been shown [24]. The group with a high CRP/albumin ratio (>0.085) had a higher clinical stage of TNM (p = 0.002) and larger primary tumors (p = 0.029) with statistically significant differences in lymph node metastasis and distant metastasis. In addition, when the CRP/albumin ratio was high, multivariate analysis showed lower survival (p = 0.002; HR = 6.078). However, all these indicators are determined in the tumor tissue by the immunohistochemical method or in blood serum, while the use of saliva for prognostic purposes can be more convenient and informative. At the same time, we obtained comparable values of the risk ratio (HR = 7.88, 95% CI 1.10–54.62, p = 0.01876), which allows us to use the proposed indicators (MDA and Na/K-ratio) for prognostic purposes in oral cancer.

The indicators selected using multivariate regression analysis statistically significantly change with the progression of OSCC (Table 3). However, they are not each independent prognostic parameters; a high HR is achieved only with a combination of MDA and the Na/K-ratio (Table 4). A detailed analysis of the data of patients revealed that for the group of favorable prognoses, the proportion of patients with early stages of OSCC is slightly higher than for the group with unfavorable prognosis (38.9 vs. 23.8%). The proportion of advanced cases (stage IV) is, on the contrary, lower in the first case (20.5 vs. 61.9%). However, the high prognostic value of MDA in combination with the Na/K-ratio can be unambiguously explained only after additional studies.

Limitations of this study are associated with a small sample size, and therefore the early stages of the disease are worse than advanced. As a comparison group, a group of patients hospitalized for the surgical treatment of neoplasms that needed to be differentiated from malignant was selected, but patients with premalignant lesions (leukoplakia) should be included in the next stage of the study. In addition, understanding the variability of saliva composition between patients, the differentiation between patients with chronic inflammatory diseases of the oral cavity or other types of cancer, as well as the standardization of the collection, processing and storage of saliva remain issues that need clarification.

5. Conclusions

In the course of the study, metabolic features of the composition of saliva in OSCC were revealed. It was shown that none of the studied parameters can be used to diagnose OSCC in an independent variant; however, the use of combinations of parameters is more informative. The high prognostic value of the MDA content and the Na/K-ratio in saliva was established before treatment. Thus, the content of MDA < 7.34 nmol/mL and the Na/K-ratio > 1.09 c.u. is a prognostically unfavorable factor (HR = 7.88, 95% CI 1.10–54.62, p = 0.01876), which may be useful for optimizing the treatment of patients with OSCC.

Author Contributions: Conceptualization, L.V.B. and V.K.K.; methodology, L.V.B.; validation, L.V.B., E.A.S. and D.V.S.; formal analysis, D.V.S.; investigation, L.V.B. and E.A.S.; resources, V.K.K.; data curation, D.V.S.; writing—original draft preparation, L.V.B. and D.V.S.; writing—review and editing, V.K.K.; visualization, D.V.S.; supervision, L.V.B.; project administration, V.K.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Panta, P.; Wong, D.T.W. Salivary Biomarkers in Oral Cancer. Oral Cancer Detect. 2019, 265–295. [CrossRef]
2. Blatt, S.; Krüger, M.; Ziebart, T.; Sagheb, K.; Schiegnitz, E.; Goetze, E.; Al-Nawas, B.; Pabst, A.M. Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: A review of the literature. J. Cranio-Maxillofac. Surg. 2017, 45, 722–730. [CrossRef]
3. Bouza, M.; Gonzalez-Soto, J.; Pereiro, R.; De Vicente, J.C.; Sanz-Medel, A. Exhaled breath and oral cavity VOCs as potential biomarkers in oral cancer patients. J. Breath Res. 2017, 11, 016015. [CrossRef] [PubMed]

4. Blatt, S.; Ziebart, T.; Krüger, M.; Pabst, A.; Information, P.E.K.F.C. Diagnosing oral squamous cell carcinoma: How much imaging do we really need? A review of the current literature. J. Craniomaxillofac. Surg. 2016, 44, 538–549. [CrossRef]

5. Chi, A.C.; Day, T.A.; Neville, B.W. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA A Cancer J. Clin. 2015, 65, 401–421. [CrossRef]

6. Kaprin, A.D.; Starinskiy, V.V.; Petrova, G.V. The Status of Cancer Care for the Population of Russia in 2018; Moscow [MNI] im. Herzen of the Ministry Of Health Of Russia: Gertsen, Russia, 2019. (In Russian)

7. Chatterjee, A.; Laskar, S.G.; Chaukar, D. Management of early oral cavity squamous cancers. Oral Oncol. 2020, 104, 104627. [CrossRef]

8. Osipyan, Y.O.; Mudunov, A.M. Computed tomography and magnetic resonance imaging in assessment of the local advancement of oral and oropharyngeal cancer as the key factor of treatment selection (literature review). Head Neck Tumors (Hnt) 2017, 7, 53–62. [CrossRef]

9. Wolff, K-D.; Follmann, M.; Nast, A. The Diagnosis and Treatment of Oral Cavity Cancer. Dtsch. Arzteblatt Online 2012, 109, 829–835. [CrossRef]

10. Rai, V.; Mukherjee, R.; Ghosh, A.K.; Routray, A.; Chakraborty, C. “Omics” in oral cancer: New approaches for biomarker discovery. Arch. Oral Biol. 2018, 87, 15–34. [CrossRef]

11. Musharraff, S.G.; Shahid, N.; Naqvi, S.M.A.; Saleem, M.; Siddiqui, A.J.; Ali, A. Metabolite Profiling of Preneoplastic and Neoplastic Lesions of Oral Cavity Tissue Samples Revealed a Biomarker Pattern. Sci. Rep. 2016, 6, 38985. [CrossRef]

12. Chi, L.-M.; Hsiao, Y.-C.; Chien, K.-Y.; Chen, S.-F.; Chuang, Y.-N.; Lin, S.-Y.; Wang, W.-S.; Chang, I.Y.-F.; Yang, C.; Chu, L.J.; et al. Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J. Proteom. 2019, 211, 103571. [CrossRef] [PubMed]

13. Roblegge, E.; Coughran, A.; Sirjani, D. Saliva: An all-rounder of our body. Eur. J. Pharm. Biopharm. 2019, 142, 133–141. [CrossRef] [PubMed]

14. Bel’skaya, L.V. Possibilities of using saliva for the diagnosis of cancer. Russ. Clin. Lab. Diagn. 2019, 64, 333–336.

15. Khurshid, Z.; Zafar, M.S.; Khan, R.S.; Najeeb, S.; Slowey, P.D.; Rehman, I.U. Role of Salivary Biomarkers in Oral Cancer Detection. Int. Rev. Cytol. 2018, 86, 23–70. [CrossRef]

16. Amenabar, J.M.; Da Silva, B.M.; Punyadeera, C. Salivary protein biomarkers for head and neck cancer. Expert Rev. Mol. Diagn. 2020, 20, 305–313. [CrossRef] [PubMed]

17. Chen, J.; Zhou, J.; Lu, J.; Xiong, H.; Shi, X.; Gong, L. Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis. BMC Cancer 2014, 14, 15. [CrossRef]

18. Geng, X.-F.; Du, M.; Han, J.-X.; Zhang, M.; Tang, X.-F.; Xing, R.-D. Saliva CA125 and TPS Levels in Patients with Oral Squamous Cell Carcinoma. Int. J. Biol. Markers 2013, 28, 216–220. [CrossRef] [PubMed]

19. Rajkumar, K.; Ramya, R.; Nandhini, G.; Rajashree, P.; Kumar, A.R.; Anandan, S.N. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma. Oral Dis. 2013, 21, 90–96. [CrossRef] [PubMed]

20. Jou, Y.-J.; Lin, C.-D.; Lai, C.-H.; Tang, C.-H.; Huang, S.-H.; Tsai, M.-H.; Chen, S.-Y.; Kao, J.-Y.; Lin, C.-W. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin. Chim. Acta 2011, 412, 1357–1365. [CrossRef]

21. Weng, L.-P.; Wu, C.-C.; Hsu, B.-L.; Chi, L.-M.; Liang, Y.; Tseng, C.-P.; Hsieh, L.-L.; Yu, J.-S. Secretome-Based Identification of Mac-2 Binding Protein as a Potential Oral Cancer Marker Involved in Cell Growth and Motility. J. Proteome Res. 2008, 7, 3765–3775. [CrossRef]

22. Feng, Y.; Li, Q.; Chen, J.; Yi, P.; Xu, X.; Fan, Y.; Cui, B.; Yu, Y.; Li, X.; Du, Y.; et al. Salivary protease spectrum biomarkers of oral cancer. Int. J. Oral Sci. 2019, 11, 7. [CrossRef] [PubMed]

23. Stott-Miller, M.; Houck, J.R.; Lohavanichbutr, P.; Méndez, E.; Upton, M.P.; Futran, N.D.; Schwartz, S.M.; Chen, C. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev. 2011, 20, 2628–2636. [CrossRef] [PubMed]

24. Park, H.-C.; Kim, M.-Y.; Kim, C.-H. C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma. J. Korean Assoc. Oral Maxillofac. Surg. 2016, 42, 243–250. [CrossRef] [PubMed]
25. Cheng, Y.-S.L.; Jordan, L.; Gorugantula, L.M.; Schneiderman, E.; Chen, H.-S.; Rees, T. Salivary Interleukin-6 and -8 in Patients With Oral Cancer and Patients With Chronic Oral Inflammatory Diseases. J. Periodontol. 2014, 85, 956–965. [CrossRef]
26. Elashoff, D.; Zhou, H.; Reiss, J.; Wang, J.; Xiao, H.; Henson, B.; Hu, S.; Arellano, M.; Sinha, U.; Le, A.; et al. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol. Biomark. Prev. 2012, 21, 664–672. [CrossRef] [PubMed]
27. Zahran, F.; Ghalwash, D.; Shaker, O.; Al-Johani, K.; Scully, C. Salivary malondialdehyde as an oxidative stress biomarker. [CrossRef]
28. Bel’Skaya, L.V.; Sarf, E.A.; Kosenok, V.K.; Gundyrev, I.A. Biochemical Markers of Saliva in Lung Cancer: Bel’Skaya, L.V.; Sarf, E.A.; Kosenok, V.K.; Gundyrev, I.A. [CrossRef]
29. Qu, S.; Zhong, Y.; Shang, R.; Zhang, X.; Song, W.; Kjems, J.; Li, H. The emerging landscape of circular RNA in life processes. RNA Biol. 2016, 14, 992–999. [CrossRef] [PubMed]
30. Lee, L.; Wong, Y.; Hsiao, H.; Wang, Y.; Chan, M.; Chang, K. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 2018, 47, 699–707. [CrossRef] [PubMed]
31. Yang, S.-F.; Huang, H.-D.; Fan, W.-L.; Jong, Y.-J.; Chen, M.-K.; Huang, C.-N.; Kuo, Y.-L.; Chung, W.-H.; Su, S.-C. Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer. Oral Oncol. 2018, 77, 1–8. [CrossRef]
32. Kaur, J.; Politis, C.; Jacobs, R. Salivary 8-hydroxy-2-deoxyguanosine, malondialdehyde, vitamin C, and vitamin E in oral pre-cancer and cancer. Diagnostic value and free radical mechanism of action. Clin. Oral Investig. 2015, 20, 315–319. [CrossRef] [PubMed]
33. Dzewulska, A.; Janiszewska-Olszowska, J.; Bachanek, T.; Grocholewicz, K. Salivary mineral composition in patients with oral cancer. Magnes. Res. 2013, 26, 120–124. [CrossRef]
34. Shigeyama, H.; Wang, T.; Ichinose, M.; Ansal, T.; Lee, S.-W. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC–MS. J. Chromatogr. B 2019, 1104, 49–58. [CrossRef]
35. Kutukova, S.I.; Manikhas, G.M.; Yaremenko, A.I.; Chukhlovin, A.B.; Belyak, N.P.; Bozhor, S.S.; Dibirov, R.K.; Ermakova, T.S. Prognostic role of laboratory and immunohistochemical markers in the recurrence of oral mucosal squamous cell carcinoma. Head Neck Tumors 2014, 3, 47–50.
36. Barak, V.; Meirovitz, A.; Leibovici, V.; Rachmut, J.; Peretz, T.; Eliahar, R.; Gross, M. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Anticancer. Res. 2015, 35, 5519–5524.
37. Bel’Skaya, L.V.; Sarf, E.A.; Kosenok, V.K.; Gundreyrev, I.A. Biochemical Markers of Saliva in Lung Cancer: Diagnostic and Prognostic Perspectives. Diagnostics 2020, 10, 186. [CrossRef]
38. Bel’Skaya, L.V.; Sarf, E.A.; Kosenok, V.K. Correlation interrelations between the composition of saliva and blood plasmain norm. Klin. Lab. Diagn. 2018, 63, 477–482.
39. Bel’Skaya, L.V.; Kosenok, V.K.; Sarf, E.A. Chronophysiologifical features of the normal mineral composition of human saliva. Arch. Oral Biol. 2017, 82, 286–292. [CrossRef] [PubMed]
40. Lé, S.; Josse, J.; Husson, F. FactoMineR: AnRPackage for Multivariate Analysis. J. Stat. Softw. 2008, 25, 1–18. [CrossRef]
41. Ogawa, T.; Washio, J.; Takahasahi, T.; Echigo, S.; Takahasahi, N. Glucose and glutamine metabolism in oral squamous cell carcinoma: Insight from a quantitative metabolomic approach. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2014, 118, 218–225. [CrossRef]
42. Ishikawa, S.; Sugimoto, M.; Kitabatake, K.; Sugano, A.; Nakamura, M.; Kaneko, M.; Ota, S.; Hiwatari, K.; Enomoto, A.; Soga, T.; et al. Identification of salivary metabolomic biomarkers for oral cancer screening. Sci. Rep. 2016, 6, 31520. [CrossRef] [PubMed]
43. Reznick, A.Z.; Hershkovich, O.; Nagler, R.M. Saliva—A pivotal player in the pathogenesis of oropharyngeal cancer. Br. J. Cancer 2004, 91, 111–118. [CrossRef]
44. Choudhri, S.K.; Chaudhary, M.; Gadhail, A.R.; Sharma, A.; Tekade, S. Oxidative and antioxidative mechanisms in oral cancer and precancer: A review. Oral Oncol. 2014, 50, 10–18. [CrossRef]
45. Khoubnasabjafari, M.; Ansarin, K.; Jouyban, A. Salivary malondialdehyde as an oxidative stress biomarker in oral and systemic diseases. J. Dent. Res. Dent. Clin. Dent. Prospect. 2016, 10, 71–74. [CrossRef] [PubMed]
46. Chole, R.; Patil, R.; Basak, A.; Palandurkar, K.; Bhowate, R.R. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. *J. Cancer Res. Ther.* 2010, 6, 487. [CrossRef]

47. Peluso, I.; Raguzzini, A. Salivary and Urinary Total Antioxidant Capacity as Biomarkers of Oxidative Stress in Humans. *Pathol. Res. Int.* 2014, 2014, 1–14. [CrossRef]

48. Hu, S.; Arellano, M.; Boontheung, P.; Wang, J.; Zhou, H.; Jiang, J.; Elashoff, D.; Wei, R.; Loo, J.A.; Wong, D.T. Salivary Proteomics for Oral Cancer Biomarker Discovery. *Clin. Cancer Res.* 2008, 14, 6246–6252. [CrossRef]

49. Patel, S.; Metgud, R. Estimation of salivary lactate dehydrogenase in oral leukoplakia and oral squamous cell carcinoma: A biochemical study. *J. Cancer Res. Ther.* 2015, 11, 119. [CrossRef]

50. Mafessoni, T.P.; Mazur, C.E.; Amenabar, J.M.; Mazur, C.E. Salivary lactate dehydrogenase (LDH) as a tool for early diagnosis of oral cancer in individuals with Fanconi anemia. *Med. Hypotheses* 2018, 119, 29–31. [CrossRef]

51. Chattopadhyay, I.; Panda, M. Recent trends of saliva omics biomarkers for the diagnosis and treatment of oral cancer. *J. Oral Biosci.* 2019, 61, 84–94. [CrossRef]

52. Jean, J.-C.; Liu, Y.; Joyce-Brady, M. The importance of gamma-glutamyl transferase in lung glutathione homeostasis and antioxidant defense. *BioFactors* 2003, 17, 161–173. [CrossRef] [PubMed]

53. Maellaro, E.; Dominici, S.; Del Bello, B.; Valentini, M.A.; Pieri, L.; Perego, P.; Supino, R.; Zunino, F.; Lorenzini, E.; Paolicchi, A.; et al. Membrane gamma-glutamyl transpeptidase activity of melanoma cells: Effects on cellular $H_2O_2$ production, cell surface protein thiol oxidation and NF-kappa B activation status. *J. Cell Sci.* 2000, 113, 2671–2678.

54. Radhika, T.; Jedd, N.; Nithya, S.; Muthumeenakshi, R.M. Salivary biomarkers in oral squamous cell carcinoma—An insight. *J. Oral Biol. Craniofac. Res.* 2016, 6, S51–S54. [CrossRef]

55. Bloniarz, J.; Rahnama, M.; Zareba, S. Influence of carcinogenesis in the oral cavity on the level of some bioelements in the saliva. *Rocz. Państwowego Zakładu Hig.* 2003, 54, 295–300.

56. Fuchs, P.N.; Rogić, D.; Vidović-Juras, D.; Susić, M.; Milenović, A.; Brailo, V.; Boras, V.V. Salivary analytes in patients with oral squamous cell carcinoma. *Coll. Antropol.* 2011, 35, 359–362.

57. Peretti, M.; Angelini, M.; Savalli, N.; Florio, T.; Yuspa, S.H.; Mazzanti, M. Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. *Biochim. Et Biophys. Acta (BBA) Biomembr.* 2015, 1848, 2523–2531. [CrossRef]

58. Miyazaki, H.; Shiozaki, A.; Nisato, N.; Ohsawa, R.; Itoi, H.; Ueda, Y.; Otsuji, E.; Yamagishi, H.; Iwasaki, Y.; Nakano, T.; et al. Chloride ions control the G1/S cell-cycle checkpoint by regulating the expression of p21 through a p53-independent pathway in human gastric cancer cells. *Biochem. Biophys. Res. Commun.* 2008, 366, 506–512. [CrossRef]

59. Mazumder, S.; Datta, S.; Ray, J.G.; Chaudhuri, K.; Chatterjee, R. Liquid biopsy: miRNA as a potential biomarker in oral cancer. *Cancer Epidemiol.* 2019, 58, 137–145. [CrossRef]